Current and emerging therapies in unresectable and recurrent gastric cancer

Erin Jou, Lakshmi Rajdev

Research output: Contribution to journalReview article

26 Citations (Scopus)

Abstract

Gastric cancer is one of the most lethal cancers worldwide despite many advances and options in therapy. As it is often diagnosed at an advanced stage, prognosis is poor with a median overall survival of less than twelve months. Chemotherapy remains the mainstay of treatment for these patients but it confers only a moderate survival advantage. There remains a need for new targeted treatment options and a way to better define patient populations who will benefit from these agents. In the past few years, there has been a better understanding of the biology, molecular profiling, and heterogeneity of gastric cancer. Our increased knowledge has led to the identification of gastric cancer subtypes and to the development of new targeted therapeutic agents. There are now two new targeted agents, trastuzumab and ramucirumab, that have recently been approved for the treatment of advanced and metastatic gastric cancer. There are also many other actively investigated targets, including epidermal growth factor receptor, the phosphatadylinositol 3-kinase/protein kinase B/mammalian target of rapamycin pathway, c-Met, poly ADP-ribose polymerase, and immune checkpoint inhibition. In this review, we discuss the current management of advanced gastric cancer as well as emerging targeted therapies and immunotherapy.

Original languageEnglish (US)
Pages (from-to)4812-4823
Number of pages12
JournalWorld Journal of Gastroenterology
Volume22
Issue number20
DOIs
StatePublished - May 28 2016

Fingerprint

Stomach Neoplasms
Therapeutics
Proto-Oncogene Proteins c-akt
Survival
Poly(ADP-ribose) Polymerases
Sirolimus
Epidermal Growth Factor Receptor
Immunotherapy
Molecular Biology
Phosphotransferases
Drug Therapy
Population
Neoplasms

Keywords

  • Advanced gastric cancer
  • Human epidermal growth factor receptor type 2
  • Immunotherapy
  • Targeted therapy
  • Vascular endothelial growth factor receptor

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Current and emerging therapies in unresectable and recurrent gastric cancer. / Jou, Erin; Rajdev, Lakshmi.

In: World Journal of Gastroenterology, Vol. 22, No. 20, 28.05.2016, p. 4812-4823.

Research output: Contribution to journalReview article

@article{e8310a1d40544af0b307bbf842b9a4c9,
title = "Current and emerging therapies in unresectable and recurrent gastric cancer",
abstract = "Gastric cancer is one of the most lethal cancers worldwide despite many advances and options in therapy. As it is often diagnosed at an advanced stage, prognosis is poor with a median overall survival of less than twelve months. Chemotherapy remains the mainstay of treatment for these patients but it confers only a moderate survival advantage. There remains a need for new targeted treatment options and a way to better define patient populations who will benefit from these agents. In the past few years, there has been a better understanding of the biology, molecular profiling, and heterogeneity of gastric cancer. Our increased knowledge has led to the identification of gastric cancer subtypes and to the development of new targeted therapeutic agents. There are now two new targeted agents, trastuzumab and ramucirumab, that have recently been approved for the treatment of advanced and metastatic gastric cancer. There are also many other actively investigated targets, including epidermal growth factor receptor, the phosphatadylinositol 3-kinase/protein kinase B/mammalian target of rapamycin pathway, c-Met, poly ADP-ribose polymerase, and immune checkpoint inhibition. In this review, we discuss the current management of advanced gastric cancer as well as emerging targeted therapies and immunotherapy.",
keywords = "Advanced gastric cancer, Human epidermal growth factor receptor type 2, Immunotherapy, Targeted therapy, Vascular endothelial growth factor receptor",
author = "Erin Jou and Lakshmi Rajdev",
year = "2016",
month = "5",
day = "28",
doi = "10.3748/wjg.v22.i20.4812",
language = "English (US)",
volume = "22",
pages = "4812--4823",
journal = "World Journal of Gastroenterology",
issn = "1007-9327",
publisher = "WJG Press",
number = "20",

}

TY - JOUR

T1 - Current and emerging therapies in unresectable and recurrent gastric cancer

AU - Jou, Erin

AU - Rajdev, Lakshmi

PY - 2016/5/28

Y1 - 2016/5/28

N2 - Gastric cancer is one of the most lethal cancers worldwide despite many advances and options in therapy. As it is often diagnosed at an advanced stage, prognosis is poor with a median overall survival of less than twelve months. Chemotherapy remains the mainstay of treatment for these patients but it confers only a moderate survival advantage. There remains a need for new targeted treatment options and a way to better define patient populations who will benefit from these agents. In the past few years, there has been a better understanding of the biology, molecular profiling, and heterogeneity of gastric cancer. Our increased knowledge has led to the identification of gastric cancer subtypes and to the development of new targeted therapeutic agents. There are now two new targeted agents, trastuzumab and ramucirumab, that have recently been approved for the treatment of advanced and metastatic gastric cancer. There are also many other actively investigated targets, including epidermal growth factor receptor, the phosphatadylinositol 3-kinase/protein kinase B/mammalian target of rapamycin pathway, c-Met, poly ADP-ribose polymerase, and immune checkpoint inhibition. In this review, we discuss the current management of advanced gastric cancer as well as emerging targeted therapies and immunotherapy.

AB - Gastric cancer is one of the most lethal cancers worldwide despite many advances and options in therapy. As it is often diagnosed at an advanced stage, prognosis is poor with a median overall survival of less than twelve months. Chemotherapy remains the mainstay of treatment for these patients but it confers only a moderate survival advantage. There remains a need for new targeted treatment options and a way to better define patient populations who will benefit from these agents. In the past few years, there has been a better understanding of the biology, molecular profiling, and heterogeneity of gastric cancer. Our increased knowledge has led to the identification of gastric cancer subtypes and to the development of new targeted therapeutic agents. There are now two new targeted agents, trastuzumab and ramucirumab, that have recently been approved for the treatment of advanced and metastatic gastric cancer. There are also many other actively investigated targets, including epidermal growth factor receptor, the phosphatadylinositol 3-kinase/protein kinase B/mammalian target of rapamycin pathway, c-Met, poly ADP-ribose polymerase, and immune checkpoint inhibition. In this review, we discuss the current management of advanced gastric cancer as well as emerging targeted therapies and immunotherapy.

KW - Advanced gastric cancer

KW - Human epidermal growth factor receptor type 2

KW - Immunotherapy

KW - Targeted therapy

KW - Vascular endothelial growth factor receptor

UR - http://www.scopus.com/inward/record.url?scp=84978770179&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84978770179&partnerID=8YFLogxK

U2 - 10.3748/wjg.v22.i20.4812

DO - 10.3748/wjg.v22.i20.4812

M3 - Review article

VL - 22

SP - 4812

EP - 4823

JO - World Journal of Gastroenterology

JF - World Journal of Gastroenterology

SN - 1007-9327

IS - 20

ER -